Pre-Hospital Mannitol for Traumatic Brain Injury (TBI)





DR.ABDULLAH IBRAHIM. HAYDARPAŞA NUMUNE E&R HOSPITAL ISTANBUL



• TBI is defined as an alteration in brain function, or other evidence of brain pathology, caused by an external force.



CLASSIFICATION OF BRAIN INJURY			
Mild	LOC less than 30 minutes	GCS 13-15	PTA less than 24 hours
Moderate	LOC greater than 30 minutes, but less than 24 hours	GCS 9-12	PTA 24 hours to 7 days
Severe	LOC greater than 24 hours	GCS 8 or less	PTA more than 7 days

Clinical signs and symptoms that suggest increased ICP include:

- 2) Headache
- 3) Nausea/vomiting
- 4) Blurre vision
- 5) Papilledema
- 6) Somnolence alter level of consciousness
- 7) Pupillary dilatation
- 8) Cushing triad
- Bradycardia
- Hypertension
- Irregular respiration



• **<u>Primary insult</u>**: Due to trauma; irreversible

<u>Secondary insult</u>: Worsening ischemia due to intracranial pressure (ICP), edema,or hypoxia

Secondary brain injury is the leading cause of inhospital deaths after traumatic brain injury

PREHOSPHTAL CARE

- Early appropriate management can have a profound impact on the patient's final outcome.
- For patients with moderate to severe head injury, provide stabilization and rapid transport to a facility with experience in the management of brain injury.



PREHOSPITAL CARE

• Issues related to treating these victims in the field or at the place of injury have lagged behind pre-hospital advancements in medical and general trauma management.

PREHOSPITAL CARE

 In the last 30 years, dedicated trauma programs have demonstrated that aggressive prehospital programs reduce morbidity and death from TBI

PREHOSPITAL CARE

 Improved outcomes following aggressive treatment of mass lesions, hypoxia, hypotension, and fluid and electrolyte abnormalities have shown that secondary events following TBI are preventable and treatable.



"I don't think it's a concussion ... although the smoke has me a little concerned."



• Mannitol as a treatment following head trauma was first described in the literature in 1961 (Wise and Chater)

• Mannitol is an osmotic diuretic (C₆H₈(OH)₆)



Mannitol

- Mannitol has two main mechanisms of action.
- Immediately after bolus administration it expands circulating volume, decreases blood viscosity and therefore increases cerebral blood flow and cerebral oxygen delivery.
- Its osmotic properties take effect in 15-30 minutes when it sets up an osmotic gradient and draws water out of neurons.

Dosage Forms

injectable solution

- 5%
- 10%
- 15%
- 20%
- 25%

Therapeutic Use

- Promotion of diuresis in the prevention or treatment of the oliguric phase of acute renal failure before irreversible renal failure becomes established.
- Reduction of intracranial pressure and brain mass.
- Reduction of high intraocular pressure when the pressure cannot be lowered by other means.
- Promotion of urinary excretion of toxic materials.

Adverse Effects

- Angina-like chest pains
- CHF
- Hypotension
- Phlebitis
- Convulsions
- Chills
- Dizziness
- Headache
- Acidosis
- Fluid/electrolyte imbalances
- Thirst
- Nausea
- Vomiting
- Blurred vision
- Urinary retention

Contraindications

- Well established anuria due to severe renal disease.
- Severe pulmonary congestion or frank pulmonary edema.
- Active intracranial bleeding except during craniotomy.
- Severe dehydration.
- Progressive renal damage or dysfunction after institution of mannitol therapy, including increasing oliguria and azotemia.
- Progressive heart failure or pulmonary congestion after institution of mannitol therapy.
- Do not administer to patients with a known hypersensitivity to mannitol.

Pre-hospital mannitol

• When to actually give mannitol in victims of head trauma has been a source of great discussion and controversy.

• In contrast to the hospital environment, the dilemma in the pre-hospital environment is the inability to look at a CT scan and characterize the injury

Pre-hospital mannitol

- If the patient has active intracranial bleeding say from an epidural hematoma, the argument <u>has been that administration</u> of mannitol wil increase the bleeding and increase the mass lesions (blood collection).
- This has led to the recommendation that without the presence of a CT scan, the <u>patient should have lateralizing signs</u> to be considered for the administration of mannitol.

 However after prolonged administration (continuous infusion) mannitol molecules move across into the cerebral interstitial space and may exacerbate cerebral oedema and raise ICP.

• Mannitol is therefore best used by bolus administration where an acute reduction in ICP is necessary.



Cerebral Edema dosage

• 1.5-2 g/kg IV infused over 30-60 minutes

• Pregnancy Category: C



Mannitol in Head Trauma: The Controversy

There are insufficient data on the effectiveness of pre-hospital administration of mannitol

The Uncertainity over use of mannitol

- All guidelines acknowledge that this is an area of considerable clinical uncertainity.
- There is uncertainity over the optimal treatment regimen ,
- over the effectiveness of mannitol as compared to other ICP lowering agents and

• over the usefulness of mannitol given at other stages following head injury, (i.e. in the pre-hospital setting)



<u>Kou Kou</u>, et al Current pre-hospital traumatic brain injury management in China <u>World J Emerg Med</u>. 2014; 5(4): 245–254.

- A literature search was conducted in January 2014 using the China National Knowledge Infrastructure (CNKI).
- Articles on the assessment and treatment of TBI in pre-hospital settings practiced by Chinese doctors were identified.

- The information on the assessment and treatment of hypoxemia, hypotension, and brain herniation was extracted from the identified articles.
- 62% of the papers claimed that their prehospital doctors assessed TBI patients' neurologic status in pre-hospital settings.

- Most of the papers showed clinical signs of brain herniation <u>by observing the patients</u>' <u>pupils and levels of consciousness</u>
- Interventions to control elevated intracranial pressure (ICP) were documented by 92% of the identified papers.

 45% of the papers documented that agents had been administered to control ICP for all TBI patients.

 The most common medications used to control ICP in Chinese pre-hospital settings were mannitol, furosemide, and corticosteroid

 Murthy et al Prehospital Care of Traumatic Brain Injury. Indian J Anaesth 2008 ;52:258

Concluded that:

- Mannitol is effective in reducing intracranial pressure and is recommended for control of ICP .
- There is however no data to support its use in patients without signs of cerebral herniation and without ICP monitoring.



Cochrane Database of Systematic Reviews

Mannitol for acute traumatic brain injury (Review)

Wakai A, McCabe A, Roberts I, Schierhout G. Mannitol for acute traumatic brain injury. *Cochrane Database of Systematic Reviews* 2013, Issue 8. Art. No.: CD001049. DOI: 10.1002/14651858.CD001049.pub5.

www.cochranelibrary.com

Mannitol for acute traumatic brain injury (Review) Copyright © 2013 The Cochrane Collaboration. Published by John Wiley & Sons, Ltd.

WILEY

Wakai A, McCabe A, Roberts I, Schierhout G.
Mannitol for acute traumatic brain injury.
Cochrane Database of Systematic Reviews 2013, Issue 8.

Objectives

- To assess the effects of : different mannitol therapy regimens, mannitol compared to other intracranial pressure (ICP) lowering agents, and
- to quantify the effectiveness of mannitol administration given at other stages following acute traumatic brain injury.

Search methods

 searched the Cochrane Injuries Group Specialised Register, CENTRAL (The Cochrane Library), MEDLINE (OvidSP), EMBASE (OvidSP), ISI Web of Science (SCI-EXPANDED & CPCI-S) and PubMed.

They found four randomized controlled trials

1. One trial compared ICP-directed therapy to 'standard care'

2. One trial compared mannitol to pentobarbital

3. One trial compared mannitol to hypertonic saline

4. One trial tested the effectiveness of prehospital administration of mannitol against placebo



 Mannitol therapy for raised ICP may have a beneficial effect on mortality when compared to pentobarbital treatment,

 but may have a detrimental effect on mortality when compared to hypertonic saline.

conclusions

- ICP-directed treatment shows a small beneficial effect compared to treatment directed by neurological signs and physiological indicators.
- There are insufficient data on the effectiveness of pre-hospital administration of mannitol.



Out-of-hospital administration of mannitol vs placebo

Sayre et al, Academic Emergency Medicine (1996)

- Sayre compared pre-hospital administration of mannitol with placebo.
- They included patients of head injury with GCS 11 or less and the patients were either administered 20% mannitol 5 ml/Kg over five minutes or placebo (0.9% saline) in equal amounts.

- This the only single prospective study thus far conducted on prehospital use of mannitol for the treatment of increased ICP.
- But it <u>did not produce clinically improved</u> <u>outcomes</u>,
- Mainly because this study was significantly underpowered, with only 20 participants

• Furthermore, no long term outcome data was reported, as patients were only followed for two hours after mannitol administration

• Evaluation of the Impact of Implementing the Emergency Medical Services Traumatic Brain Injury Guidelines in Arizona: The Excellence in Prehospital Injury Care (EPIC) Study Methodology

• Academic Emergency Medicine 2014;21:818–830 © 2014 by the Society for Academic Emergency Medicine

The review stated that:

 An ideal therapeutic agent for ICP reduction should reduce ICP while maintaining cerebral perfusion (pressure).

- While mannitol can cause dehydration over time, HTS helps maintain normovolemia and cerebral perfusion, a finding that has led to a large amount of pilot data being published on the benefits of HTS, albeit in small cohorts.
- Prophylactic therapy is not recommended with mannitol, although it may be beneficial with HTS

- The review found that treatment with mannitol for increased intracranial pressure reduced the likelihood of death when compared to treatment with pentobarbital.
- In contrast, it found that treatment with mannitol may increase the likelihood of death when compared to treatment with hypertonic saline.

- The review also found a small benefit when mannitol treatment is directed by measurement of intracranial pressure compared to 'standard treatment.'
- The review found insufficient data on the effectiveness of pre-hospital administration of mannitol





The Brain Trauma Foundation's Guidelines for the Management of Severe Traumatic Brain Injury 4th Edition (2016)

The Brain Trauma Foundation's Guidelines for the Management of Severe Traumatic Brain Injury 4th Edition (2016)

 Mannitol is effective for control of raised intracranial pressure (ICP) at doses of 0.25 g/kg to 1 g/kg body weight. Arterial hypotension (systolic blood pressure 90mmhg should be avoided.



 Restrict mannitol use prior to ICP monitoring to patients with signs of transtentorial herniation or progressive neurological deterioration not attributable to extracranial causes. The Brain Trauma Foundation's Guidelines for the Management of Severe Traumatic Brain Injury 4th Edition (2016)

• The Committee is universal in its belief that hyperosmolar agents are useful in the care of patients with severe TBI.

• However, the literature does not currently support recommendations that meet the strict criteria for contemporary evidenced-based medicine approaches for guideline development.



- The recommendations in the 3rd Edition of these guidelines about administration of hyperosmolar agents were based on
 and Class a study and nine Class a studies
- one Class 2 study and nine Class 3 studies.

Summary

 For patients with moderate to severe head injury,provide stabilization and rapid transport to a facility with experience in the management of brain injury.

• The goals of care during prehospital triage, stabilization, and transport are to recognize life-threatening raised intracranial pressure and to circumvent cerebral herniation

Summary

- Mannitol for reduction of ICP in TBI has been used since 1961
- Most of trials and publication have concentrated on the hospital environment
- Very few trails for the pre-hospital administration of mannitol
- There are no class I trials only class II & III trials



- For pre- hospital administration of mannitol use The Brain Trauma Foundation's Guidelines for the Management of Severe Traumatic Brain Injury 4th Edition.
- Mannitol is effective for control of raised intracranial pressure (ICP) at doses of 0.25 g/kg to 1 g/kg body weight. Arterial hypotension (systolic blood pressure 90mmhg should be avoided.



 Restrict mannitol use prior to ICP monitoring to patients with signs of transtentorial herniation or progressive neurological deterioration not attributable to extracranial causes.

• If transport times are short, do not give mannitol or hypertonic saline for elevated ICP.

Summary

- Prolonged administration (continuous infusion) mannitol may exacerbate cerebral oedema and raise ICP.
- Mannitol is therefore best used by bolus administration where an acute reduction in ICP is necessary.

Finally

"Half of what you'll learn in medical school will be shown to be either dead wrong or out of date within five years of your graduation; the trouble is that nobody can tell you which half -- so the most important thing to learn is how to learn on your own..."

-Dr. David Sackett, evidence-based medicine pioneer

• THANK YOU FOR YOU PATIENCE